Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + pm-Pac + carboplatin as first-line therapy for advanced squamous NSCLC
ChiCTR2500113012Phase 4Recruiting
- Sponsor
- Mianyang Central Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in Pulmonary squamous cell carcinoma, sponsored by Mianyang Central Hospital. Primary endpoints: Objective response rate and Progression-free survival. Started Nov 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2500113012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113012.